Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoine Italiano

Showing results (221-230 of 418) with videos related to

Pageof 42
Sort By:
International Journal of Cancer|January 25, 2008
HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent ampliconAntoine Italiano, Laurence Bianchini, Frédérique Keslair, et al.
Scientific Reports|December 22, 2017
A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and OutcomePauline Rochefort, Antoine Italiano, Valérie Laurence, et al.
The Lancet. Oncology|October 23, 2012
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism studyIsabelle Ray-Coquard, Jean-Yves Blay, Antoine Italiano, et al.
Cancer|February 3, 2011
ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcomaAntoine Italiano, Armelle Laurand, Audrey Laroche, et al.
Targeted Oncology|November 13, 2013
Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trialNicolas Penel, Isabelle Ray-Coquard, Christine Bal-Mahieu, et al.
Gynecologic Oncology|April 1, 2022
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 studyRonnie Shapira-Frommer, Linda Mileshkin, Ludmila Manzyuk, et al.
European Journal of Cancer (Oxford, England : 1990)|July 11, 2025
The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patientsAntoine Italiano, Othilie Gautier, Jules Dupont, et al.
Cell Reports. Medicine|February 5, 2025
Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structuresFlorent Peyraud, Jean-Philippe Guégan, Christophe Rey, et al.
Journal for Immunotherapy of Cancer|August 11, 2025
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumorsMichele Maio, Victor Moreno, Juan Martin-Liberal, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2018
Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcomaThomas Brodowicz, Olivier Mir, Jennifer Wallet, et al.
Pageof 42

Showing results (221-230 of 418) with videos related to

Sort By:
Pageof 42
International Journal of Cancer|January 25, 2008
HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent ampliconAntoine Italiano, Laurence Bianchini, Frédérique Keslair, et al.
Scientific Reports|December 22, 2017
A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and OutcomePauline Rochefort, Antoine Italiano, Valérie Laurence, et al.
The Lancet. Oncology|October 23, 2012
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism studyIsabelle Ray-Coquard, Jean-Yves Blay, Antoine Italiano, et al.
Cancer|February 3, 2011
ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcomaAntoine Italiano, Armelle Laurand, Audrey Laroche, et al.
Targeted Oncology|November 13, 2013
Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trialNicolas Penel, Isabelle Ray-Coquard, Christine Bal-Mahieu, et al.
Gynecologic Oncology|April 1, 2022
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 studyRonnie Shapira-Frommer, Linda Mileshkin, Ludmila Manzyuk, et al.
European Journal of Cancer (Oxford, England : 1990)|July 11, 2025
The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patientsAntoine Italiano, Othilie Gautier, Jules Dupont, et al.
Cell Reports. Medicine|February 5, 2025
Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structuresFlorent Peyraud, Jean-Philippe Guégan, Christophe Rey, et al.
Journal for Immunotherapy of Cancer|August 11, 2025
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumorsMichele Maio, Victor Moreno, Juan Martin-Liberal, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2018
Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcomaThomas Brodowicz, Olivier Mir, Jennifer Wallet, et al.
Pageof 42